A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2009-07-27
Target enrollment:
Participant gender:
Summary
Phase IIa, randomised, double-blind, double-dummy, parallel group, multi-centre study in
subjects diagnosed with moderate chronic obstructive pulmonary disease (COPD). The primary
objective is to evaluate the effects of 12-weeks of treatment with GW856553 7.5 mg twice
daily (BID) compared with placebo on the percentage of sputum neutrophils at 12 weeks. Twelve
weeks of treatment with SERETIDE 50/500 BID will be compared with placebo for effect on
sputum neutrophils as a positive control arm in the study
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination